Compugen CGEN
NASDAQ CGEN
$2.59 +0.03 (+1.17%)
As of: Sep 4, 2026 · 2:34 PM EDT

Compugen (CGEN) Net Income towards Common Stockholders (2009 - 2026)

Compugen (CGEN) posted quarterly Net Income towards Common Stockholders of $7.7 million for Q1 2026, up 7.59% year-over-year from $7.1 million in Q1 2025, and down 86.5% on a QoQ basis from $56.7 million in Q4 2025.

Analysis

Compugen (CGEN) Net Income towards Common Stockholders (2009 - 2026) Analysis & Trends

Compugen has reported Net Income towards Common Stockholders for 18 years, with the latest figure at $7.7 million in Q1 2026.

  • Net Income towards Common Stockholders for Q1 2026 came in at $7.7 million, up 7.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $35.9 million (up 772.34% YoY), and the FY2025 annual result was $35.3 million, up 348.35% from the prior year.
  • Net Income towards Common Stockholders eased to $7.7 million in Q1 2026, from $56.7 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $56.7 million in Q4 2025 and troughed at -$28.0 million in Q2 2023.
  • A 5-year average of $1.4 million and a median of -$3.1 million in 2022 frame the typical range for Net Income towards Common Stockholders.
  • The widest annual swing landed in 2023, when Net Income towards Common Stockholders tumbled 198.03%; it then jumped 1027.53% in 2025.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$3.1 million in 2022, then jumped by 414.13% to $9.7 million in 2023, then slumped by 162.98% to -$6.1 million in 2024, then jumped by 1027.53% to $56.7 million in 2025, then sank by 86.5% to $7.7 million in 2026.
  • Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $7.7 million in Q1 2026, $56.7 million in Q4 2025, and -$6.9 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 138.74 Bn 130.89 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.52 Bn 77.52 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn 472.00 Mn
4 Moderna 58.04 Bn 52.91 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.06 Bn 44.06 Bn - -644.37 Mn
6 BeOne Medicines 39.98 Bn 34.88 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.46 Bn 32.15 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.41 Bn 27.57 Bn - 81.49 Mn
9 Insmed 27.44 Bn 26.28 Bn 358.27 Mn -13.27 Mn
10 Compugen 241.50 Mn 155.89 Mn -92,000.00 -22.31 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -22.31 Mn
Mar 31, 2026 7.66 Mn
Dec 31, 2025 56.74 Mn
Sep 30, 2025 -6.90 Mn
Jun 30, 2025 -21.61 Mn
Mar 31, 2025 7.12 Mn
Dec 31, 2024 -6.12 Mn
Sep 30, 2024 10.28 Mn
Jun 30, 2024 -16.62 Mn
Mar 31, 2024 7.26 Mn
Dec 31, 2023 9.79 Mn
Sep 30, 2023 -9.85 Mn
Jun 30, 2023 -28.00 Mn
Mar 31, 2023 9.31 Mn
Dec 31, 2022 -3.03 Mn
Sep 30, 2022 -11.75 Mn
Jun 30, 2022 28.56 Mn
Mar 31, 2022 -9.71 Mn
Dec 31, 2021 -6.63 Mn
Sep 30, 2021 -8.18 Mn